_256_384.jpg)
Healthcare | June 27, 2024
Glenmark and IADVL undertake awareness campaign supporting vitiligo patients in India
Glenmark released Picture Post Cards on World Vitiligo Day
Glenmark released Picture Post Cards on World Vitiligo Day
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Subscribe To Our Newsletter & Stay Updated
